PMID- 24594096
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140312
LR  - 20220317
IS  - 1758-5996 (Print)
IS  - 1758-5996 (Electronic)
IS  - 1758-5996 (Linking)
VI  - 6
IP  - 1
DP  - 2014 Mar 4
TI  - Fenofibrate improves endothelial function and plasma myeloperoxidase in patients 
      with type 2 diabetes mellitus: an open-label interventional study.
PG  - 30
LID - 10.1186/1758-5996-6-30 [doi]
AB  - BACKGROUND: Fenofibrate offers a number of benefits on the cardiovascular system 
      and it is plausible that its anti-inflammatory, anti-oxidant and anti-fibrotic 
      effects and enhancement of cardiac metabolic performances may account for its 
      direct cardioprotective effects.In this study we aimed to investigate the effect 
      of fenofibrate on endothelial function assesed by vascular studies and levels of 
      soluble E-selectin (sE-selectin) as well as the effect on plasma myeloperoxidase 
      (MPO) in patients with type 2 diabetes mellitus (T2DM) without previous use of 
      lipid-lowering medication. METHODS: 27 patients (14 men and 13 women) with T2DM 
      and good glycemic control (HbA1c: min 5.9%, max: 7.1%) treated with metformin 
      monotherapy, without previous use of lipid-lowering medication were enrolled in 
      this study. Vascular studies included measures of brachial artery diameter before 
      and after release of a suprasystolic ischemia. FMD was calculated as the percent 
      (%) change in arterial diameter following reactive hyperemia. Student's paired t 
      test and Wilcoxon Signed Ranks Test were used to compare values before and after 
      fenofibrate therapy. RESULTS: Fenofibrate therapy significantly increased post 
      ischemia mean brachial artery diameter at 60 s (from 4.7 [4.4; 5.0] mm to 4.9 
      [4.6; 5.2] mm, p = 0.01) and at 90 s (from 4.7 [4.4; 5.0] mm to 4.9 [4.6; 5.1], p 
      = 0.02). FMD response to hyperaemia at 60 s increased with 4.5 +/- 13.7% (median 
      value pre- treatment: 22.2%, median value post- treatment 25.0%, z = -2.9, p = 
      0.004). After 8 weeks of fenofibrate therapy, plasma MPO levels decreased to 49.5 
      [30.3; 71.5] ng/ml (% change from baseline = 4.6%, z = -2.2, p = 0.03) and mean 
      plasma sE-selectin levels decreased to 67.1 [54.4; 79.8] ng/ml, (% change from 
      baseline = 2.6%, p = 0.03). CONCLUSION: In patients with T2DM without previous 
      treatment for dyslipidemia, short-term treatment with fenofibrate improved 
      vascular endothelial function as demonstrated by increased post ischemia mean 
      brachial artery diameter, increased FMD and decreased plasma sE-selectin and 
      favorably affected plasma MPO levels. Therefore, fenofibrate may be considered a 
      protective cardiovascular drug in this group of patients. TRIAL REGISTRATION: 
      (Australian New Zealand Clinical Trials Registry ANZCTR12612000734864).
FAU - Nita, Cristina
AU  - Nita C
AD  - Department of Diabetes, Nutrition and Metabolic Diseases, "Iuliu Hatieganu" 
      University of Medicine and Pharmacy Cluj-Napoca, 2-4 Clinicilor Street, 400006 
      Cluj-Napoca, Romania.
FAU - Bala, Cornelia
AU  - Bala C
AD  - Department of Diabetes, Nutrition and Metabolic Diseases, "Iuliu Hatieganu" 
      University of Medicine and Pharmacy Cluj-Napoca, 2-4 Clinicilor Street, 400006 
      Cluj-Napoca, Romania.
FAU - Porojan, Mihai
AU  - Porojan M
AD  - Department of Internal Medicine, "Iuliu Hatieganu" University of Medicine and 
      Pharmacy Cluj-Napoca, 4-6 Clinicilor Street, 400006 Cluj-Napoca, Romania.
FAU - Hancu, Nicolae
AU  - Hancu N
AD  - Department of Diabetes, Nutrition and Metabolic Diseases, "Iuliu Hatieganu" 
      University of Medicine and Pharmacy Cluj-Napoca, 2-4 Clinicilor Street, 400006 
      Cluj-Napoca, Romania.
LA  - eng
PT  - Journal Article
DEP - 20140304
PL  - England
TA  - Diabetol Metab Syndr
JT  - Diabetology & metabolic syndrome
JID - 101488958
PMC - PMC3974011
EDAT- 2014/03/07 06:00
MHDA- 2014/03/07 06:01
PMCR- 2014/03/04
CRDT- 2014/03/06 06:00
PHST- 2013/10/08 00:00 [received]
PHST- 2014/02/13 00:00 [accepted]
PHST- 2014/03/06 06:00 [entrez]
PHST- 2014/03/07 06:00 [pubmed]
PHST- 2014/03/07 06:01 [medline]
PHST- 2014/03/04 00:00 [pmc-release]
AID - 1758-5996-6-30 [pii]
AID - 10.1186/1758-5996-6-30 [doi]
PST - epublish
SO  - Diabetol Metab Syndr. 2014 Mar 4;6(1):30. doi: 10.1186/1758-5996-6-30.